Loading…
Recursion Pharmaceuticals, Inc. is projected to rise to $3.63 by 2027, a +21% move from its current price of $3.00. RXRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $2.91 | $3.00 | $3.10 | +0.07% |
| Aug 3 | $2.88 | $3.00 | $3.14 | +0.15% |
| Aug 4 | $2.85 | $3.01 | $3.17 | +0.22% |
| Aug 5 | $2.83 | $3.01 | $3.20 | +0.29% |
| Aug 6 | $2.81 | $3.01 | $3.23 | +0.37% |
| Aug 7 | $2.79 | $3.01 | $3.25 | +0.44% |
| Aug 8 | $2.78 | $3.02 | $3.27 | +0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.78 | $3.02 | $3.27 | +0.52% |
| Week 2 | $2.70 | $3.03 | $3.40 | +1.04% |
| Week 3 | $2.65 | $3.05 | $3.51 | +1.56% |
| Week 4 | $2.60 | $3.06 | $3.60 | +2.08% |
| Week 5 | $2.57 | $3.08 | $3.69 | +2.61% |
| Week 6 | $2.53 | $3.09 | $3.78 | +3.14% |
| Week 7 | $2.51 | $3.11 | $3.86 | +3.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
RXRX is a healthcare stock with a current price of $3.02 and a market capitalization of $1.6B. It is ranked 2174 by market capitalization among listed assets.
The current price outlook reflects a defined path in the near term, with a 2026 average price of $3.02 and a 0% ROI, followed by a transition to a bullish trajectory in subsequent years as indicated by higher forecast averages and growing ROIs through 2050. The forecast projects an average price of $14.56 with a 382.1% ROI by 2050, underscoring meaningful upside potential alongside substantial uncertainty inherent to long-range equity forecasts.
For 2027 the forecast shows an average price of $3.66 with a 21.3% ROI and a bullish sentiment, continuing to rise in the following years (e.g., 2028 avg $4.19, ROI 38.6%; 2030 avg $3.88, ROI 28.4%), culminating in a 2040 average of $8.46 (ROI 180%) and a 2050 average of $14.56 (ROI 382.1%). These figures describe a pathway to higher prices over time while acknowledging the variability captured in the range of possible outcomes.
A major floor 26.2% below — a decisive break under it would weaken the trend.
The nearest floor, 3.7% below — buyers have tended to step in here.
The nearest ceiling, 32.0% above — a clean break opens room to run.
A major ceiling 45.1% above — clearing it would confirm fresh momentum.
Key RXRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RXRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.01 | Sell | $3.01 | Sell |
| MA 10 | $3.00 | Buy | $3.05 | Sell |
| MA 20 | $3.24 | Sell | $3.15 | Sell |
| MA 50 | $3.30 | Sell | $3.27 | Sell |
| MA 100 | $3.31 | Sell | $3.43 | Sell |
| MA 200 | $3.91 | Sell | $3.87 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.10 | Neutral |
| Stoch RSI (14) | 68.79 | Neutral |
| CCI (20) | -54.69 | Neutral |
| Williams %R (14) | -75.56 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -9.37 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 24.44 | Neutral |
| TRIX (15) | -0.41 | Sell |
| Awesome (5,34) | -0.28 | Sell |
| Ultimate (7,14,28) | 47.36 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 3.02 | Sell |
| ADX (14) | 17.31 | Neutral |
| ATR (14) | 0.09 | Info |
The 30-day technical picture shows bearish sentiment with an RSI of 40. The 50-day moving average sits at $3.33.
The 200-day moving average is at $4.04, placing near-term price action under the longer-term trend. Support stands at $3.02 and resistance at $3.96, indicating a narrow trading band near current levels.
The 30-day price range spans from a low of $2.36 to a high of $3.87, highlighting recent volatility within a tight vicinity of the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.84 | $3.00 | $4.30 | 0% | Neutral | |
| $2.86 | $3.63 | $4.88 | +21% | Bullish | |
| $3.04 | $3.98 | $5.59 | +33% | Bullish | |
| $3.01 | $4.05 | $5.87 | +35% | Bullish | |
| $2.93 | $4.03 | $6.01 | +34% | Bullish | |
| $2.92 | $4.11 | $6.27 | +37% | Bullish | |
| $3.23 | $4.64 | $7.23 | +55% | Bullish | |
| $3.90 | $5.71 | $9.06 | +90% | Bullish | |
| $4.04 | $6.01 | $9.71 | +100% | Bullish | |
| $4.13 | $6.26 | $10.27 | +109% | Bullish | |
| $5.14 | $8.43 | $14.80 | +181% | Bullish | |
| $8.09 | $15.24 | $29.50 | +408% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.84 | $3.00 | $3.83 | +0.00% |
| September 2026 | $2.73 | $3.24 | $3.97 | +8.09% |
| October 2026 | $2.68 | $3.21 | $3.97 | -1.06% |
| November 2026 | $2.73 | $3.29 | $4.11 | +2.50% |
| December 2026 | $2.81 | $3.41 | $4.30 | +3.59% |
Click any year to see its month-by-month RXRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RXRX to range from $2.84 to $4.30 through 2026. The $3.00 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The RXRX price prediction for 2027 points to an average of $3.63 (low $2.86, high $4.88) — a potential gain of +21% on today's $3.00. Momentum favours further upside here.
In 2028, RXRX is projected to trade between $3.04 and $5.59, averaging $3.98 — a potential gain of +33% from today's $3.00. That is up +10% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Recursion Pharmaceuticals, Inc.'s 2029 outlook centres on $4.05, within a $3.01 to $5.87 range. That is up +2% on the projected 2028 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2030, RXRX could reach as high as $6.01, with a base case around $4.03 and support toward $2.93 — roughly +34% from $3.00. Buyers look set to stay in control over this stretch.
Expect RXRX to range from $2.92 to $6.27 through 2031. The $4.11 average target implies a +37% move from current prices. That is up +2% on the projected 2030 average. Momentum favours further upside here.
The RXRX price prediction for 2032 points to an average of $4.64 (low $3.23, high $7.23) — a potential gain of +55% on today's $3.00. Buyers look set to stay in control over this stretch.
In 2033, RXRX is projected to trade between $3.90 and $9.06, averaging $5.71 — a potential gain of +90% from today's $3.00. That is up +23% on the projected 2032 average. Momentum favours further upside here.
Recursion Pharmaceuticals, Inc.'s 2034 outlook centres on $6.01, within a $4.04 to $9.71 range. That is up +5% on the projected 2033 average. That marks a +100% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, RXRX could reach as high as $10.27, with a base case around $6.26 and support toward $4.13 — roughly +109% from $3.00. Momentum favours further upside here.
Expect RXRX to range from $5.14 to $14.80 through 2040. The $8.43 average target implies a +181% move from current prices. That is up +35% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The RXRX price prediction for 2050 points to an average of $15.24 (low $8.09, high $29.50) — a potential gain of +408% on today's $3.00. Momentum favours further upside here.
Investing $1,000 in RXRX today (≈ 333.333333 RXRX) could be worth
$5,081.43
+$4,081.43 (+408%) by 2050 · US Dollar
Based on the average projected RXRX price of $15.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RXRXwould be worth at today's price.
$1,000 invested in RXRX on Jul 31, 2025 (≈ 168.067232 RXRX) would be worth
$504.2
-$495.8 (-49.6%) today · 0.50× · US Dollar
Based on a RXRX entry price of $5.95 vs. today's $3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.96 | $1,013.51 | +1.4% |
| 1 month ago | $3.67 | $817.44 | -18.3% |
| 3 months ago | $3.39 | $884.96 | -11.5% |
| 6 months ago | $4.18 | $717.7 | -28.2% |
| 1 year ago | $5.95 | $504.2 | -49.6% |
| All time (5.0y) ago | $30.24 | $99.21 | -90.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RXRX forecast.
Our base-case forecast reaches $6.00 around 2034.
Implied market cap at $6.00: $3.15B
The multi-year forecast paints a bullish arc after 2026, with the average price rising from $3.02 in 2026 to $3.66 in 2027 and $3.88 in 2030, before accelerating toward higher levels through 2050.
Key milestones include a 2027 average of $3.66 (ROI 21.3%), 2028 average of $4.19 (ROI 38.6%), 2033 average of $5.65 (ROI 87.1%), 2040 average of $8.46 (ROI 180%), and a 2050 average of $14.56 (ROI 382.1%). The sentiment is marked as BULLISH across most years after 2026, with 2026 itself labeled NEUTRAL and a 0% ROI.
These are estimate-based projections and not guarantees. They reflect the presented numerical forecast and should be considered within the inherent uncertainties of long-range market outcomes.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $3.88 with a range from $2.69 to $6.06 and a 28.4% ROI. The sentiment is BULLISH.
Forecasts show bullish sentiment in multiple years with an average price reaching $14.56 by 2050 and a 382.1% ROI, though 2026 is neutral with an average of $3.02 and a 0% ROI.
Yes. In 2033 the average is $5.65 with a maximum of $9.50, indicating a potential to exceed $5 in that year.
The 2040 forecast shows an average of $8.46, a range of $4.67 to $15.95, and a 180% ROI, with a bullish sentiment.
Recursion Pharmaceuticals, Inc. Community Discussion
0Share your Recursion Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.